Clinical trial · Observational

The Association of hsCRP and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma

An Explorative Study on the Association of High Sensitivity C-Reactive Protein (hsCRP) and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma

NCT04303975CI-TRIAL-00045483unknownClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The primary purpose of this study is to explore the association of high sensitivity C-reactive protein (hsCRP) and radiotherapy(RT)-induced toxicity in patients with nasopharyngeal carcinoma. In each patient, hsCRP levels in the pre- and post-RT plasma samples will be measured according to the schedule we set.

Conditions

Conditions (3)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Head and Neck Cancer	Malignant Head and Neck Neoplasm	ALIAS	0.90
Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma	ONTOLOGY_EXACT	0.98
Toxicity Due to Radiotherapy	—	UNRESOLVED	—

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
clinical measurements	Other	—	UNRESOLVED

Design

Arms and outcomes

Arms (2)

label
Group 1: Patients with neoadjuvant chemotherapy
description
The patients of group1 will receive one of the following treatments: 1. neoadjuvant chemotherapy \& concurrent chemoradiotherapy 2. neoadjuvant chemotherapy \& radiotherapy 3. neoadjuvant chemotherapy \& radiotherapy \& adjuvant chemotherapy
interventionNames
1. Other: clinical measurements
label
Group 2: Patients without neoadjuvant chemotherapy
description
The patients of group2 will receive one of the following treatments: 1. concurrent chemoradiotherapy 2. concurrent chemoradiotherapy \& adjuvant chemoradiotherapy 3. radiotherapy \& adjuvant chemotherapy
interventionNames
1. Other: clinical measurements

Primary outcomes (2)

measure
hsCRP levels
timeFrame
Through treatments completion，12 weeks

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 70 Years

Show eligibility criteria text

Inclusion Criteria:

* Patients were pathologically newly diagnosed with nasopharyngeal carcinoma and had no previous history of other tumors
* According to the treatment strategies of doctors, patients need to receive radiotherapy with or without chemotherapy (for example, neoadjuvant chemotherapy, concurrent chemotherapy, adjuvant chemotherapy) or targeted therapy
* Willingness to sign the informed consent and return to enrolling institution for follow-up and data collection

Exclusion Criteria:

* Patients do not conform to the inclusion criteria
* Pregnant or Nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception
* Vital organs dysfunction(for example, kidneys, heart, liver, lungs, brain)
* Other contraindications or unsuitable conditions for radiotherapy

References

Publications (0)

Data not yet available

No reference posted for this study.